Home › Research › Tau biomarkers
Identification of genetic modifiers of autosomal dominant Alzheimer's disease: a genome-wide association study
Patel M, Feng W, Mckay NS, Millar PR, Liu M, Yang C, Cetin A, Johnson M et al.. The Lancet. Neurology, 2026-06-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background Individuals with autosomal dominant Alzheimer's disease (ADAD) arising from mutations in PSEN1, PSEN2, or APP exhibit variability in clinical presentation. Genetic studies of ADAD have shaped our understanding of the disease, and the discovery of genetic modifiers can inform therapeutic interventions and improve patient outcomes. We aimed to discover new genetic modifiers in individuals with mutations in the three ADAD genes.
What this study adds
Evidence grade: Low
The record lists 2,338 participants. This genome-wide association study aimed to find genetic modifiers in people with mutations in PSEN1, PSEN2, or APP that cause autosomal dominant Alzheimer's disease. It may inform future therapeutic targets but does not itself report any treatment, cure, or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Patel, M., Feng, W., Mckay, N. S., Millar, P. R., Liu, M., Yang, C., et al. (2026). Identification of genetic modifiers of autosomal dominant Alzheimer's disease: a genome-wide association study. The Lancet. Neurology. https://doi.org/10.1016/s1474-4422(26)00123-7
Vancouver
Patel M, Feng W, Mckay NS, Millar PR, Liu M, Yang C, et al. Identification of genetic modifiers of autosomal dominant Alzheimer's disease: a genome-wide association study. The Lancet. Neurology. 2026. doi:10.1016/s1474-4422(26)00123-7. PMID: 42127933.
BibTeX
@article{patel2026-42127933,
author = {Patel, M. and Feng, W. and Mckay, N. S. and Millar, P. R. and Liu, M. and Yang, C. and Cetin, A. and Johnson, M. and others},
title = {{Identification of genetic modifiers of autosomal dominant Alzheimer's disease: a genome-wide association study}},
journal = {The Lancet. Neurology},
year = {2026},
doi = {10.1016/s1474-4422(26)00123-7},
pmid = {42127933},
url = {https://doi.org/10.1016/s1474-4422(26)00123-7}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Genetic studies of ADAD have shaped our understanding of the disease, and the discovery of genetic modifiers can inform therapeutic interventions and improve patient outcomes.
- We aimed to discover new genetic modifiers in individuals with mutations in the three ADAD genes.
- Methods In this genome-wide association study, we analysed data from participants in three study cohorts (the Knight Alzheimer Disease Research Center [Knight-ADRC], the Dominantly Inherited Alzheimer Network [DIAN] observational study, and the Alzheimer Disease Sequencing Project [ADSP] R4).
- We did whole-genome sequencing on 101 unrelated, non-Hispanic, White, symptomatic participants with ADAD mutations and 5050 asymptomatic, unrelated control participants.
Why it matters
This genome-wide association study aimed to find genetic modifiers in people with mutations in PSEN1, PSEN2, or APP that cause autosomal dominant Alzheimer's disease. It may inform future therapeutic targets but does not itself report any treatment, cure, or prevention.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants2,338
- Evidence strengthLow
How this study scored 48/100
Published in a leading specialty journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 46 of the 96 points we could judge it on, which is 48 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (The Lancet. Neurology) |
| Journal's citation record | 3 / 4 | The Lancet Neurology: journal h-index 457 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 3 / 4 | 2,338 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.5 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 3 / 6 | Cited 4.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Jalen Scott holds only 8 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 6 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42127933) |
| Free to read | 2 / 2 | Free to read |
| Points | 46 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 46 of the 96 points we could judge it on is 48 out of 100. |
| Total | 48 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/s1474-4422(26)00123-7
- PubMed: 42127933
- Original source →
- Free full text: The Lancet Neurology →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Tau biomarkers from nearby years
Also in Tau biomarkers
60 studies in the library are filed under Tau biomarkers with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Tau biomarkers hub.